Praxis Precision hits milestone in fight against rare paediatric seizures
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Subscribe To Our Newsletter & Stay Updated